ABSTRACT
Structural analogues of leukotriene B4 (LTB4) were designed based on the plausible conformation of LTB4 (1). Joining C-7-C-9 of the conformer A or B into an aromatic ring system led to the discovery of benzene analogues 2, 4 and 6a. Joining C-4-C-9 of the conformer C or D into an aromatic ring system led to the discovery of analogues 3, 5 and 7. The compounds examined in this study were evaluated as to their inhibition of [3H] LTB4 binding to human neutrophils, and by a secondary intact human neutrophil functional assay for agonist/antagonist activity. The first analogues prepared, compounds 2-7, demonstrated moderate potency in the LTB4 receptor binding assay. The modification of these compounds by the introduction of another substituent into the aromatic ring produced a marked increase in receptor binding (28c, IC50 = 0.020 microM; 38c, IC50 = 0.020 microM; 52a, IC50 = 0.020 microM; 52b, IC50 = 0.018 microM). Most of these structural analogues of LTB4 demonstrated agonist activity. Of the analogues prepared in this study, only compound 57 demonstrated weak LTB4 receptor antagonist activity, at 10 microM.
Subject(s)
Leukotriene B4/analogs & derivatives , Receptors, Leukotriene B4/metabolism , Cell Aggregation/drug effects , Humans , Leukotriene B4/chemistry , Leukotriene B4/metabolism , Models, Molecular , Neutrophils/cytology , Neutrophils/metabolismABSTRACT
A series of trisubstituted benzenes which demonstrate leukotriene B4 (LTB4, 1) receptor affinity was prepared. Previous trisubstituted benzenes from our laboratory showed high affinity to the LTB4 receptor but demonstrated agonist activity in functional assays. Compound 3a, the initial lead compound of this new series, showed only modest affinity (IC50 = 0.20 microM). However, 3a was a receptor antagonist with no demonstrable agonist activity up to 30 microM. Further modification of the lipid tail and aryl head groups region led to the discovery of 3b (ONO-4057). This compound, free of agonist activity, possesses high affinity to the LTB4 receptor (Ki = 3.7 +/- 0.9 nM).
Subject(s)
Benzene Derivatives/pharmacology , Receptors, Leukotriene B4/antagonists & inhibitors , Benzene Derivatives/chemistry , Cell Aggregation/drug effects , Humans , Leukotriene B4/metabolism , Neutrophils/cytology , Neutrophils/metabolism , Receptors, Leukotriene B4/chemistry , Structure-Activity RelationshipSubject(s)
Leukotriene B4/antagonists & inhibitors , Phenylpropionates/pharmacology , Animals , Binding, Competitive , Leukotriene B4/metabolism , Neutrophils/metabolism , Phenylpropionates/chemical synthesis , Rats , Receptors, Immunologic/metabolism , Receptors, Leukotriene B4 , Structure-Activity RelationshipABSTRACT
(p-Amylcinnamoyl)anthranilic acid (3a) had moderate antagonist activities against LTD4-induced smooth muscle contraction on guinea pig ileum and LTC4-induced bronchoconstriction in anesthetized guinea pigs. Modifications were made in the hydrophobic part (cinnamoyl moiety) and the hydrophilic part (anthranilate moiety) of 3a. A series of 8-(benzoylamino)-2-tetrazol-5-yl-1,4-benzodioxans and 8-(benzoylamino)-2-tetrazol-5-yl-4-oxo-4H-1-benzopyrans were revealed to be potent antagonists of leukotrienes C4 and D4. Among both series, ONO-RS-347 (18k) and ONO-RS-411 (19h) were the most potent and orally active antagonists, respectively. Structure-activity relationships are discussed.